Aviceda Completes Enrollment in Part 1 of the SIGLEC Phase 2/3 U.S. Clinical Trial; Initiation of Part 2 Imminent
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 23, 2023--<a ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct 23, 2023--<a ...
DUBLIN--(BUSINESS WIRE)--Oct 23, 2023--The <a ...
JERSEY CITY, N.J.--(BUSINESS WIRE)--Oct 22, 2023--Today, Celltrion USA announced that the U.S. Food and Drug Administration (FDA) has approved ZYMFENTRA 庐 (infliximab-dyyb) for maintenance therapy in adults with moderately to severely active ulcerative colitis (UC) and Crohn蘑菇视频 disease (CD) ...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Oct 22, 2023--Updated results from a subgroup analysis of a first-in-human <a ...
RAHWAY, N.J.--(BUSINESS WIRE)--Oct 21, 2023--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the Phase 3 LITESPARK-005 trial investigating WELIREG, Merck蘑菇视频 first-in-class, oral hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor, for the ...
MADISON, N.J.--(BUSINESS WIRE)--Oct 20, 2023--LEO Pharma A/S, a global leader in medical dermatology, will present a catalog of new clinical and real-world data around tralokinumab-ldrm in the treatment of moderate-to-severe atopic dermatitis (AD). The drug is marketed in the U.S. as Adbry 庐 ...